|
PL3765615T3
(pl)
|
2018-03-14 |
2023-11-13 |
Arbor Biotechnologies, Inc. |
Nowe enzymy i układy crispr ukierunkowane na dna
|
|
CN121555430A
(zh)
|
2018-05-11 |
2026-02-24 |
比姆医疗股份有限公司 |
使用可编程碱基编辑器系统取代病原性氨基酸的方法
|
|
US12522812B2
(en)
|
2018-05-16 |
2026-01-13 |
Arbor Biotechnologies, Inc. |
CRISPR-associated systems and components
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
KR20210139265A
(ko)
*
|
2019-02-13 |
2021-11-22 |
빔 테라퓨틱스, 인크. |
표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법
|
|
US20220235347A1
(en)
|
2019-02-13 |
2022-07-28 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
US12569438B2
(en)
|
2019-07-29 |
2026-03-10 |
Georgia Tech Research Corporation |
Nanomaterials containing constrained lipids and uses thereof
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US12435035B2
(en)
|
2020-01-09 |
2025-10-07 |
Guide Therapeutics, Llc |
Nanomaterials
|
|
CA3170326A1
(en)
*
|
2020-02-13 |
2021-08-19 |
Beam Therapeutics Inc. |
Compositions and methods for engraftment of base edited cells
|
|
KR20230009379A
(ko)
*
|
2020-03-31 |
2023-01-17 |
아버 바이오테크놀로지스, 인크. |
Cas12i2 변이체 폴리펩타이드를 포함하는 조성물 및 이의 용도
|
|
CA3194019A1
(en)
*
|
2020-09-04 |
2022-03-10 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
US20240018550A1
(en)
*
|
2020-12-01 |
2024-01-18 |
Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) |
Adenine base editor having increased thymine-cytosine sequence-specific cytosine editing activity, and use thereof
|
|
WO2022119294A1
(ko)
*
|
2020-12-01 |
2022-06-09 |
한양대학교 산학협력단 |
사이토신 교정 활성이 제거된 아데닌 염기교정 유전자가위 및 이의 용도
|
|
KR20230131863A
(ko)
|
2021-01-20 |
2023-09-14 |
빔 테라퓨틱스, 인크. |
나노물질
|
|
IL303845A
(en)
|
2021-01-20 |
2023-08-01 |
Beam Therapeutics Inc |
Nanomaterials include a degradable property
|
|
CN115704015B
(zh)
*
|
2021-08-12 |
2025-08-12 |
清华大学 |
基于腺嘌呤和胞嘧啶双碱基编辑器的靶向诱变系统
|
|
CN115772512B
(zh)
*
|
2021-09-07 |
2025-12-23 |
华东师范大学 |
腺嘌呤脱氨酶、包含其的腺嘌呤碱基编辑器及其应用
|
|
WO2023052366A1
(en)
|
2021-09-28 |
2023-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
|
CN119286831A
(zh)
*
|
2021-10-21 |
2025-01-10 |
复旦大学 |
碱基编辑器及其构建方法与应用
|
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
|
EP4452925A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Nanomaterial comprising diamines
|
|
EP4452942A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Nanomaterials comprising disulfides
|
|
EP4452930A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Ionizable amine and ester lipids and lipid nanoparticles
|
|
CA3241488A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
WO2023121971A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Nanomaterials comprising tetravalent lipid compounds
|
|
US20250161492A1
(en)
|
2022-01-25 |
2025-05-22 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of beta-thalassemia
|
|
WO2023169454A1
(zh)
*
|
2022-03-08 |
2023-09-14 |
中国科学院遗传与发育生物学研究所 |
腺嘌呤脱氨酶及其在碱基编辑中的用途
|
|
CN117925585A
(zh)
*
|
2022-04-07 |
2024-04-26 |
尧唐(上海)生物科技有限公司 |
腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途
|
|
CN120456933A
(zh)
|
2022-04-28 |
2025-08-08 |
布罗德研究所股份有限公司 |
编码碱基编辑器的aav载体及其用途
|
|
CN114686456B
(zh)
*
|
2022-05-10 |
2023-02-17 |
中山大学 |
基于双分子脱氨酶互补的碱基编辑系统及其应用
|
|
EP4522647A1
(en)
|
2022-05-10 |
2025-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from beta-thalassemia
|
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
|
CN119923466A
(zh)
*
|
2022-06-15 |
2025-05-02 |
比姆医疗股份有限公司 |
用于减少补体激活的组合物和方法
|
|
EP4543469A2
(en)
*
|
2022-06-27 |
2025-04-30 |
Beam Therapeutics Inc. |
Compositions and methods for non-genotoxic cell conditioning
|
|
WO2024019936A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
EP4558633A1
(en)
|
2022-07-22 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from beta-thalassemia
|
|
WO2024086596A1
(en)
*
|
2022-10-18 |
2024-04-25 |
4M Genomics Inc. |
Polypeptide fusions or conjugates for gene editing
|
|
JP2026506554A
(ja)
|
2023-02-06 |
2026-02-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
多重塩基編集による遺伝子改変造血幹細胞の濃縮
|
|
EP4705461A2
(en)
*
|
2023-05-03 |
2026-03-11 |
Beam Therapeutics Inc. |
Compositions and methods for treating stargardt disease
|
|
WO2024230760A1
(zh)
*
|
2023-05-09 |
2024-11-14 |
北京齐禾生科生物科技有限公司 |
一种可作用于dna的腺苷脱氨酶及其应用
|
|
CN118871578A
(zh)
|
2023-05-24 |
2024-10-29 |
锐正基因(苏州)有限公司 |
用于碱基编辑的脱氨酶及其变体
|
|
WO2025038821A1
(en)
*
|
2023-08-16 |
2025-02-20 |
Chroma Medicine, Inc. |
Methods and compositions for multiplex epigenetic editing
|
|
WO2025059520A1
(en)
*
|
2023-09-15 |
2025-03-20 |
Beam Therapeutics Inc. |
Compositions and methods for base editing a phenylalanine hydroxylase polynucleotide
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
CN120290534A
(zh)
*
|
2024-01-10 |
2025-07-11 |
上海数因信科智能科技有限公司 |
腺嘌呤脱氨酶、包含其的碱基编辑器融合蛋白和碱基编辑器系统及其应用
|
|
CN117568313B
(zh)
*
|
2024-01-15 |
2024-04-26 |
上海贝斯昂科生物科技有限公司 |
基因编辑组合物及其用途
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025202473A1
(en)
*
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
US20250332260A1
(en)
|
2024-04-10 |
2025-10-30 |
Garuda Therapeutics, Inc. |
Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
|
|
WO2025228273A1
(zh)
*
|
2024-04-28 |
2025-11-06 |
广州瑞风生物科技有限公司 |
脱氨酶、单碱基编辑器及其应用
|